Annual Drug Patent Expirations for JENTADUETO+XR
Jentadueto Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge.
JENTADUETO XR drug price trends.
Drug patent litigation for JENTADUETO XR.
The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
